These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 36215069)

  • 1. COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.
    Marquez C; Kerkhoff AD; Schrom J; Rojas S; Black D; Mitchell A; Wang CY; Pilarowski G; Ribeiro S; Jones D; Payan J; Manganelli S; Rojas S; Lemus J; Jain V; Chamie G; Tulier-Laiwa V; Petersen M; DeRisi J; Havlir DV
    JAMA Netw Open; 2022 Oct; 5(10):e2235844. PubMed ID: 36215069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Nakakubo S; Kishida N; Okuda K; Kamada K; Iwama M; Suzuki M; Yokota I; Ito YM; Nasuhara Y; Boucher RC; Konno S
    Lancet Infect Dis; 2023 Nov; 23(11):1244-1256. PubMed ID: 37399831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
    Townsley H; Gahir J; Russell TW; Greenwood D; Carr EJ; Dyke M; Adams L; Miah M; Clayton B; Smith C; Miranda M; Mears HV; Bailey C; Black JRM; Fowler AS; Crawford M; Wilkinson K; Hutchinson M; Harvey R; O'Reilly N; Kelly G; Goldstone R; Beale R; Papineni P; Corrah T; Gilson R; Caidan S; Nicod J; Gamblin S; Kassiotis G; Libri V; Williams B; Gandhi S; Kucharski AJ; Swanton C; Bauer DLV; Wall EC
    PLoS One; 2024; 19(3):e0294897. PubMed ID: 38512960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.
    ; Thompson MG; Yoon SK; Naleway AL; Meece J; Fabrizio TP; Caban-Martinez AJ; Burgess JL; Gaglani M; Olsho LEW; Bateman A; Lundgren J; Grant L; Phillips AL; Groom HC; Stefanski E; Solle NS; Ellingson K; Lutrick K; Dunnigan K; Wesley MG; Guenther K; Hunt A; Mak J; Hegmann KT; Kuntz JL; Bissonnette A; Hollister J; Rose S; Morrill TC; Respet K; Fowlkes AL; Thiese MS; Rivers P; Herring MK; Odean MJ; Yoo YM; Brunner M; Bedrick EJ; Fleary DE; Jones JT; Praggastis J; Romine J; Dickerson M; Khan SM; Lamberte JM; Beitel S; Webby RJ; Tyner HL
    JAMA; 2022 Oct; 328(15):1523-1533. PubMed ID: 36255426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
    Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
    JAMA Netw Open; 2023 Feb; 6(2):e231181. PubMed ID: 36853602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022.
    Hansen C; Perofsky AC; Burstein R; Famulare M; Boyle S; Prentice R; Marshall C; McCormick BJJ; Reinhart D; Capodanno B; Truong M; Schwabe-Fry K; Kuchta K; Pfau B; Acker Z; Lee J; Sibley TR; McDermot E; Rodriguez-Salas L; Stone J; Gamboa L; Han PD; Duchin JS; Waghmare A; Englund JA; Shendure J; Bedford T; Chu HY; Starita LM; Viboud C
    JAMA Netw Open; 2022 Dec; 5(12):e2245861. PubMed ID: 36484987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort.
    Wee LE; Lim JT; Tay AT; Chiew CJ; Ong B; Lye DCB; Lahiri M; Tan KB
    JAMA Netw Open; 2024 Aug; 7(8):e2430983. PubMed ID: 39212988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom.
    Vihta KD; Pouwels KB; Peto TE; Pritchard E; House T; Studley R; Rourke E; Cook D; Diamond I; Crook D; Clifton DA; Matthews PC; Stoesser N; Eyre DW; Walker AS;
    Clin Infect Dis; 2022 Aug; 76(3):e133-41. PubMed ID: 35917440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Menni C; Valdes AM; Polidori L; Antonelli M; Penamakuri S; Nogal A; Louca P; May A; Figueiredo JC; Hu C; Molteni E; Canas L; Österdahl MF; Modat M; Sudre CH; Fox B; Hammers A; Wolf J; Capdevila J; Chan AT; David SP; Steves CJ; Ourselin S; Spector TD
    Lancet; 2022 Apr; 399(10335):1618-1624. PubMed ID: 35397851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19-Related Symptoms during the SARS-CoV-2 Omicron (B.1.1.529) Variant Surge in Japan.
    Akaishi T; Kushimoto S; Katori Y; Sugawara N; Egusa H; Igarashi K; Fujita M; Kure S; Takayama S; Abe M; Kikuchi A; Ohsawa M; Ishizawa K; Abe Y; Imai H; Inaba Y; Iwamatsu-Kobayashi Y; Nishioka T; Onodera K; Ishii T
    Tohoku J Exp Med; 2022 Sep; 258(2):103-110. PubMed ID: 36002251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 infection in children evaluated in an ambulatory setting during Delta and Omicron time periods.
    Smith H; Mahon A; Moss A; Rao S
    J Med Virol; 2023 Jan; 95(1):e28318. PubMed ID: 36397139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and Post-Acute COVID-19 Outcomes Among Immunologically Naïve Adults During Delta Versus Omicron Waves.
    Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
    medRxiv; 2022 Nov; ():. PubMed ID: 36425923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic.
    de Hoog MLA; Sluiter-Post JGC; Westerhof I; Fourie E; Heuvelman VD; Boom TT; Euser SM; Badoux P; Reusken C; Bont LJ; Sanders EAM; Jaddoe VWV; Herpers BL; Eggink D; Wildenbeest JG; Duijts L; van Houten MA; Bruijning-Verhagen PCJL
    JAMA Netw Open; 2022 Oct; 5(10):e2237522. PubMed ID: 36264578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.